Qyuns Therapeutics (2509) Fundamentals 2026 — P/E 9.9x, Revenue Analysis | SniperIQ
Qyuns Therapeutics (2509) is a CN-listed Healthcare company in Biotechnology with a market capitalization of HK
Qyuns Therapeutics (2509) has a market capitalization of approximately HK
Qyuns Therapeutics's trailing twelve-month P/E ratio is 9.9x, with a price-to-book (P/B) of 4.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
Qyuns Therapeutics runs a net profit margin of 39.0%, a gross margin of 88.5%, and an operating margin of 40.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Qyuns Therapeutics reported revenue of ¥786M for fiscal year 2025, with net income of ¥306M and earnings per share (EPS) of 1.37. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Qyuns Therapeutics does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Qyuns Therapeutics carries a debt-to-equity ratio of 0.84x and a current ratio of 2.22x, with a market beta of 1.47. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Qyuns Therapeutics (2509) the key facts are: market cap HK
Get Qyuns Therapeutics's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.